The low tissue concentrations of tetrahydrobiopterin, as well as the antagonism between the catecholamine feedback inhibition of tyrosine hydroxylase and the reduced cofactor concentrations, suggest that dihydropteridine reductase may play an important role in the regulation of catecholamine biosynthesis.
The hydroxylation of tyrosine to dihydroxyphenylalanine (DOPA) is considered to be the rate-limiting step in catecholamine biosynthesis(l). This step, however, is quite complex and it is not known which of its components is actually the limiting factor in the overall reaction. Tyrosine hydroxylase requires molecular oxygen and a reduced pteridine as cofactors (2) (3) (4) . In addition, a pteridine-reducing system is required to reduce the pteridine cofactor that is continuously oxidized during the reaction. Adrenal dihydropteridine reductase has been found in bovine adrenal glands (5) . This enzyme reduces the pteridine cofactor oxidized in the hydroxylation of tyrosine to DOPA, allowing cyclic and catalytic use of the cofactor.
The effect of a tetrahydropteridine-generating system on the in vitro activity of tyrosine hydroxylase is reported in the present communication. In addition, since there are several indications from in vivo and in vitro experiments that tyrosine hydroxylase activity is controlled, at least in part, by a feedback end-product inhibition, the effects of catecholamines on the entire in vitro system were also studied.
Abbreviations: DMPH4, 6,7-dimethyl-5,6,7,8-tetrahydropterine; Q-DMPH2, quinonoid form of 6,7-dimethyldihydropterine; 7,8-DMPH2, 6,7-dimethyl-7,8-dihydropterine, DOPA, 3,4-dihydroxyphenylalanine.
MATERIALS AND METHODS
The reduced pteridine, 6,7-dimethyl-5,6,7,8-tetrahydropterine (DMPH4), was purchased from Calbiochem. Biopterin was generously donated by Smith Kline and French Laboratories. [3,5-3H ]L-Tyrosine (1000 Ci/mol) was purchased from Amersham Searle; it was purified by passage through a Dowex 50W-X4 K+ column, and the purified material was diluted to a specific activity of 10 Ci/mol. Tris(hydroxymethyl) aminomethane (Trizma base), TPN+, D-glucose-6-phosphate, and glucose-6-phosphate dehydrogenase (crude powder from Baker's Yeast, 0.3-1.0 units/mg) were obtained from Sigma Chemical Co. Beef liver catalase, 2X crystallized, an aqueous suspension, 150,000 units/ml, was purchased from Worthington Biochemical Corp., and 2-mercaptoethanol was purchased from Eastman Organic Chemicals. All other chemicals were obtained from standard commercial sources. Deionized glass-distilled water was used for the preparation of all reagents and buffers.
Preparation of enzymes
Beef adrenal dihydropteridine reductase was prepared by a modification of the method of Kaufman for the sheepliver enzyme (6) . Frozen beef adrenal medullae were homogenized with 1.5 volumes of 0.03 M acetic acid for 1 min at 4°C in a Waring Blendor at full speed. Another 1.5 volumes of 0.03 M acetic acid was added and the homogenization was continued for 0.5 min. The homogenate was centrifuged for 20 min at 10,000 X g. To each 100 ml of supernatant, 29.3 g of ammonium sulfate was added (to 50% saturation). The mixture was centrifuged for 20 min at 10,000 X g; the residue was discarded. Another 17.5 g of ammonium sulfate per 100 ml of ammonium sulfate-treated supernatant was added (to 80%o saturation). Centrifugation was repeated and the supernatant was discarded. The precipitate was dissolved in 5%O of the original homogenate supernatant volume with 0.01 M Tris -HCl, (pH 7.4) and dialyzed overnight against 100 volumes of the same buffer. The next morning, the buffer was changed and dialysis was continued for 8 hr. The dialyzed enzyme preparation was divided into small fractions and stored frozen. Dihydropteridine reductase is exclusively localized in the 100,000 X g supernatant fraction; all attempts to detect enzyme activity in the different particulate subcellular fractions have failed. An ammonium sulfate fraction of tyrosine hydroxylase was prepared by a modification of the method of Nagatsu et al. (2) as described by Wurzburger and Musacchio (7) . Trypsin-treated tyrosine , also determined in 0.1 M Tris * HC1 (pH 6. 1), was obtained after a preparation of Q-DMPH2 had been allowed to stand for 24 hr at room temperature.
hydroxylase was prepared by the procedure of Petrack et al. (8) . This trypsin-treated tyrosine hydroxylase was preferentially used because the tyrosine hydroxylase prepared by the procedure of Nagatsu et al. contains some dihvdropteridine reductase activity, which obscures the effects of added dihydropteridine reductase. All experiments were performed at 40C unless otherwise indicated.
Preparation of pteridines 6,7-Dimethyl-5,6,7,8-tetrahydropterine was oxidized to the quinonoid isomer dimethyldihydropterine (Q-DMPH2) by a modification of the 2,6-dichlorophenolindophenol method described by Kaufman (9) . DMPH4, 10 jmol, was dissolved in 5 ml of water; immediately, 12,umol of 2,6-dichlorophenolindophenol in 5 ml of water were added. Complete oxida- tion was instantaneous; the quinonoid dihydropteridine was extracted three times with 10-12 ml of ether to purify it from the dye. All traces of ether were removed with a stream of nitrogen. The length of time from the oxidation of DMPH4 to the addition of the quinoid DMPH2 to the incubation tubes was 4 min. It is critical to keep this time as short as possible since Q-DMPH2 isomerizes very rapidly to the inactive 7,8-DMPH2. The spectrum of the oxidized pteridine, immediately after preparation, indicated that the compound was substantially in the quinonoid form (Fig. 1) . The inactive dihydro form, 7,8-DMPH2, was obtained from Q-DMPH2 after several hours of incubation at room temperature. As shown in Fig.  1 , a spectrum showed the pteridine to be completely converted to the 7,8 form. Dihydrobiopterin was prepared from biopterin with a modification of the method of Pohland et al. (10) as follows: 10 Mmol of biopterin was dissolved in 1 ml of 1 N HCl containing 10 mg of platinum oxide. The solution was bubbled with hydrogen for 1 hr at 55°C and rapidly filtered through a Buchner funnel with a fritted disc. The pH of the filtrate was adjusted to 5.5 with 0.25 M Tris. Tetrahydrobiopterin was immediately oxidized to the quinonoid dihydro form by titration with a solution of 2,6-dichlorophenolindophenol in water (2.4,umol/ml); the yield of tetrahydrobiopterin obtained by the hydrogenation procedure was measured by the amount of dichlorophenolindophenol used to oxidize it to the quinonoid dihydro form. The dihydrobiopterin formed was rapidly prepared free from the dye according to the above procedure and used immediately.
Enzyme assay Dihydropteridine reductase activity was detected indirectly by the use of a tyrosine hydroxylase system that requires a reduced pteridine to hydroxylate tyrosine to dihydroxyphenylalanine(DOPA). This system was found to be more efficient if a TPNH-generating system was included. The complete assay system for dihydropteridine reductase contained the The different components of the tyrosine hydroxylase-dihydropteridine reductase system were all adjusted to obtain maximal rates of DOPA formation in the presence of dihydropteridine reductase and minimal rates without the enzyme. The concentration of TPNH used in these experiments is 10-fold lower than the concentration used previously (5), in order to reduce the amount of Q-DMPH2 that is nonenzymatically reduced to DMPH4 by high concentrations of TPNH. The low level of TPNH (1 X 10-5 M) was kept constant with a TPNH-generating system (glucose-f-phosphate and glucose-f-phosphate dehydrogenase). The results in Tables 1 and 2 indicate that the synthesis of DOPA is dependent on the presence of dihydropteridine reductase. The results described in Table 1 also demonstrate that the production of DOPA is dependent on TPNH; in the absence of TPN+ or glucose-f-phosphate, there is no synthesis of DOPA. The production of DOPA was markedly reduced by omission of glucose-6-phosphate dehydrogenase in the experiment described in Table 1 . However, the requirements for glucose-fphosphate dehydrogenase are variable with the different enzyme preparations, probably because of the presence of different amounts of glucose-f-phosphate dehydrogenase in the tyrosine hydroxylase or in the dihydropteridine reductase preparations. The TPNH-generating system does not require the addition of MgCl2, probably because some traces of metals are already present in the enzyme preparations. The dihydropteridine reductase prepared as indicated in Methods was found free of TPN + reducing properties in the absence of a TPNH-generating system. In contrast, the enzyme prepared with the method previously described (5) could reduce nucleotides without an added nucleotide-reducing system.
The production of DOPA in the tyrosine hydroxylasedihydropteridine reductase system is nearly linear with time for 30 min, but the rate of DOPA production is slightly slower during the first few minutes of the incubation, probably due to the low initial concentrations of DMPH4.
As is demonstrated in Table 2 , dihydropteridine reductase can reduce only the quinonoid form of DMPH2. The 7,8-DMPH2 isomer is not reduced to DMPH4, as indicated by its inability to sustain the hydroxylation of tyrosine to DOPA. Moreover, the dihydropterdine reductase prepared as indicated in Methods is free of tetrahydrofolate reductase activity, as demonstrated by the incapacity of the enzyme to reduce 7,8-DMPH2, and by the lack of effect of methotrexate on the production of DOPA ( Table 2 ).
Effects of catecholamines
The effects of epinephrine were tested on a complete system containing various amounts of dihydropteridine reductase. As shown in Fig. 2 , a marked inhibition of DOPA formation is produced by an epinephrine concentration of 2 X 10-s M.
It is also evident that, within certain limits, the epinephrine inhibition can be antagonized by increasing concentrations of dihydropteridine reductase. Similar results are obtained when the quinonoid form of dihydrobiopterin is used instead of Q-DMPH2.
The inhibition of tyrosine hydroxylase by catecholamines has been described as competitive with DMPH4 (12, 13); as indicated in Fig. 3 , this inhibition is also competitive with the natural cofactor, tetrahydrobiopterin. It was suggested, however, that catecholamines could react directly with the pteridine cofactor and produce the same kinetic changes as if there was a competition for a tyrosine hydroxylase site (14) . In order to investigate this possibility, the effects of epinephrine on the spectrum of DMPH4 were studied under conditions similar to those at which the competition between epinephrine and DMPH4 is demonstrated. The results illustrated in Fig. 4 demonstrate that the addition of epinephrine does not produce any change in the spectrum of DMPH4 that would indicate oxidation of the tetrahydropteridine. In a similar The complete assay system was the same as that indicated under Materials and Methods, with the use of trypsin-treated tyrosine hydroxylase; the pteridine cofactors Q-DMPH2 and 7,8-DMPH2 were prepared as described, and each at a final concentration of 0.1 Amol/ml, was tested for cofactor activity. Activity was also determined with each cofactor in the presence of methotrexate (1 X 10-5 M). Controls contained all components for the assay except dihydropteridine reductase. Blank activity, determined without dihydropteridine reductase and tyrosine hydroxylase, was equivalent to 1.0 nmol. The results are the average of two determinations.
experiment not illustrated here, the rate of oxidation of DMPH4 was followed by measurment of the rate of decrease in absorbance at 302 nm; this rate was found to be identical before and after the addition of epinephrine. As can be observed in Fig. 4 , the magnitude of these changes is negligible if it is considered that the competition experiments between epinephrine and DMPH4 on tyrosine hydroxylase activity are finished 9 min after the addition of epinephrine. In addition, it should be noted that, due to optical interferences, the spectrophotometric measurements on the effects of epinephrine on DMPH4 were performed with a mercaptoethanol concentration that is 10-fold lower than that used for the determinations of tyrosine hydroxylase activity. Therefore, even slower changes may be expected with the higher mercaptoethanol concentrations used in the enzymatic studies.
DISCUSSION
The production of DOPA in the tyrosine hydroxylase-dihydropteridine reductase system described is completely dependent on both enzymes and their substrates and cofactors. Ferrous iron and catalase are not essential components, but they stimulate the formation of DOPA; ferrous iron has been described to be a requirement for tyrosine hydroxylase activity (2, 8) . However, Shiman et at. (15) have recently indicated that the stimulatory effects of ferrous iron may be due to its ability to decompose H202; this phenomenon may also explain why we have been unable to observe the stimulatory effects of iron in the presence of catalase. Catalase has a marked stimulatory effect on this system; its mechanism of action is unknown, but is presumably related to its ability to decompose H202. Catalase protects liver phenylalanine hydroxylase from inactivation during incubation (16); it is conceivable that it may also protect one or both enzymes in our system, and thereby increase the formation of DOPA. After a short lag period, the production of DOPA is linear for at least 30 min. The initial lag period is expected because (a) tyrosine hydroxylase itself shows an initial lag period when it is not preincubated with DMPH4, and (b) the production of DOPA can start only after enough DMPH4 is formed to serve as cofactor for tyrosine hydroxylase.
Adrenal-medulla dihydropteridine reductase can reduce the quinonoid forms of DMPH2 and dihydrobiopterin as previously demonstrated (5); this enzyme is different from tetrahydrofolate dehydrogenase (EC 1.5.1.3), as indicated by its inability to reduce 7,8-DMPH2 and by its resistance to methotrexate inhibition. All the characteristics of adrenal dihydropteridine reductase examined indicate that the enzyme is similar to the liver dihydropteridine reductase described by Kaufman (6) .
The production of DOPA in the system described is, within certain limits, proportional to the activity of dihydropteridine reductase. This assay for dihydropteridine reductase can be used to quantitate the enzyme activity, providing precautions are taken to keep the results within the proportional range.
Adrenal dihydropteridine reductase is found only in the soluble fraction of the homogenate (as described in Methods) and tyrosine hydroxylase is a cytoplasmic enzyme (17, 18, 7) . Obviously, the location of both enzymes has important implications regarding the regulation of catecholamine synthesis: the amine pool that regulates tyrosine hydroxylase activity should necessarily be located in the cell cytoplasm. Weiner and Selvaratnam (19) and Kopin et al. (20) have shown that in adrenergic nerves, tyrosine hydroxylase activity is regulated by a cytoplasmic catecholamine pool. Therefore, (0.05 /hmol/ml) was determined in 0.1 M Tris-HCl (pH 6.1). Epinephrine, 0.05 ,smol/ml, was then added to the cuvette containing the DMPH4 and also to the cuvette containing the blank; the spectrum of DMPH4 was redetermined. The figure on the left compares the initial spectrum of DMPH4 ( ) to that of DMPH4 1.5 min after the addition of epinephrine ---); the small decrease in absorbance of the total spectrum reflects a slight dilution of DMPH4 after the addition of epinephrine. The figure on the right compares the spectrum of DMPH4 1.5 min, 10 min, and 30 min after the addition of epinephrine. (22) , and in the brain it has been estimated as 0.75 ug/g (23) . If we assume that the pteridine cofactor is uniformly distributed in the adrenal medullary cells, the cofactor concentrations can be calculated to be between 2 X 10-6 M and 1 X 10-5 M. These concentrations are 100-to 500-fold lower than those used for the in vitro assays. The concentration of cofactor in the brain adrenergic structures cannot even be roughly calculated, since the relative volume of these structures and the distribution of the cofactor are unknown. There is additional evidence that the concentration of pteridine cofactor, at least under certain conditions, may be rate limiting. C6tA et al. (24) reported that the addition of tetrahydrofolic acid or biopterin to chick sympathetic chain cultures significantly increases their catecholamine content.
The concentrations of tyrosine and 02 used in these experiments are slightly higher than their in vivo concentrations, but since these concentrations are in the range of their respective Michaelis constants, no major increases in synthesis rates can be attributed to the slightly higher concentrations used in vitro. All these considerations indicate that the marked differences in the activity of tyrosine hydroxylase in vivo and in vitro could be explained by the different cofactor concentrations.
Our in vitro experiments indicate that dihydropteridine reductase can increase the activity of tyrosine hydroxylase and it can antagonize the inhibitory effects of catecholamines. The mechanism by which dihydropteridine reductase antagonizes the catecholamine inhibition is most likely due to an increased concentration of reduced pteridine cofactor. The competitive nature of the antagonism between catecholamines and the reduced pteridine cofactor analog DMPH4 was described by Udenfriend et al. (13) . It has recently been suggested that this competition may be due to a direct chemical oxidation of the cofactor to an inactive form, instead of a true competition for enzyme sites (14) . Our experiments, however, rule out the possibility of a direct interaction between cofactor and catecholamines. In addition, we have demonstrated that the natural cofactor for adrenal tyrosine hydroxylase, tetrahydrobiopterin, also inhibits competitively the inhibitory action of catecholamines on tyrosine hydroxylase.
CONCLUSIONS
In vitro experiments indicate that, under certain conditions, the rate of tyrosine hydroxylase activity can be controlled by dihydropteridine reductase, and that this enzyme can antagonize the catecholamine inhibition of tyrosine hydroxylase. Since the concentration of the natural cofactor seems to be rate limiting in vivo, it is suggested that the activity of dihydropteridine reductase may be an important factor in the determination of the in vivo rates of catecholamine synthesis and of the effectiveness of the catecholamine feedback inhibition.
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